SeaStar Medical Holding Corporation (ICU)
| Market Cap | 13.79M -41.7% |
| Revenue (ttm) | 1.71M +123.6% |
| Net Income | -13.63M |
| EPS | -3.81 |
| Shares Out | 4.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,712 |
| Open | 3.090 |
| Previous Close | 3.090 |
| Day's Range | 3.050 - 3.165 |
| 52-Week Range | 2.070 - 12.500 |
| Beta | -1.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About ICU
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SC... [Read more]
Financial Performance
In 2025, SeaStar Medical Holding's revenue was $1.23 million, an increase of 814.07% compared to the previous year's $135,000. Losses were -$12.15 million, -51.07% less than in 2024.
Financial StatementsNews
SeaStar Medical Holding Earnings Call Transcript: Q2 2026
QUELIMMUNE revenue grew 82% year-over-year in Q2 2026, with adoption doubling among top pediatric hospitals. NEUTRALIZE-AKI trial for adult AKI is progressing, with enrollment on track and regulatory milestones supported by FDA designations.
SeaStar Medical Holding Earnings release: Q2 2026
SeaStar Medical Holding released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
SeaStar Medical Holding Quarterly report: Q2 2026
SeaStar Medical Holding has published its Q2 2026 quarterly earnings report on August 12, 2026.
SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
Added 3 top-rated children's hospitals to QUELIMMUNE ® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025
SeaStar Medical Holding Slides: Investor presentation
SeaStar Medical Holding has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026
DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients fa...
SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)
Sponsors educational summit of leading pediatric AKI health care experts Announces best practices webinar to further advance new treatment options DENVER, July 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Med...
SeaStar Medical Holding Transcript: Investor Summit Virtual Conference
SCD therapy targets hyperinflammation at its source, showing strong survival benefits and no device-related adverse events in pediatric AKI, with a robust pipeline expanding into adult and cardiorenal indications. Commercialization is advancing, supported by FDA approvals, CMS reimbursement, and a clean financial position.
SeaStar Medical announces new CD-10-PCS codes for SCD therapy
SeaStar Medical (ICU) announced that its Selective Cytopheretic Device, or SCD, therapy has received dedicated ICD-10-PCS codes from the Centers for Medicare & Medicaid Services, or CMS. This assignme...
SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury
Enables standardized inpatient hospital billing for QUELIMMUNE ® (SCD-PED) therapy
SeaStar Medical to Present at Upcoming Investor Summit Conference
DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients fa...
SeaStar Medical price target raised to $8 from $6 at Maxim
Maxim analyst Anthony Vendetti raised the firm’s price target on SeaStar Medical (ICU) to $8 from $6 and keeps a Buy rating on the shares. The company’s Q1 revenue, gross…
SeaStar Medical Holding Earnings Call Transcript: Q1 2026
QUELIMMUNE net revenue grew 69% year-over-year in Q1 2026, with seven new hospital adoptions and strong gross margins. The NEUTRALIZE-AKI pivotal trial for adult AKI is progressing, and the SAVE Registry reached 50-patient enrollment. Cash reserves increased to $9.3 million.
SeaStar Medical Holding Earnings release: Q1 2026
SeaStar Medical Holding released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
SeaStar Medical Holding Quarterly report: Q1 2026
SeaStar Medical Holding has published its Q1 2026 quarterly earnings report on May 13, 2026.
SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates
Added 7 top-rated children's hospitals to QUELIMMUNE ® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue Advanced enrollment in ...
SeaStar Medical Holding Registration statement: Registration filing
SeaStar Medical Holding filed a registration statement on May 7, 2026, providing details about a securities offering with the SEC.
SeaStar Medical to Report First Quarter Financial Results on May 13, 2026
DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing ...
SeaStar Medical Holding Proxy statement: Proxy filing
SeaStar Medical Holding filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
SeaStar Medical Holding Registration statement: Registration filing
SeaStar Medical Holding filed a registration statement on April 28, 2026, providing details about a securities offering with the SEC.
SeaStar Medical showcases new data from SAVE Registry
SeaStar Medical (ICU) announced the presentations of new SAVE Registry data and investigator led research on the mechanism of action of the selective cytopheretic device therapy at the 31st Internatio...
SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026
Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data
SeaStar Medical Holding Earnings Call Transcript: Q4 2025
QUELIMMUNE sales and adoption surged in 2025, driving revenue growth and improved margins. SCD therapy for adult AKI advanced in pivotal trials, with strong cash position and reduced losses supporting expansion into larger markets.
SeaStar Medical Holding Annual report: Q4 2025
SeaStar Medical Holding has published its Q4 2025 annual report on March 25, 2026.
SeaStar Medical Holding Earnings release: Q4 2025
SeaStar Medical Holding released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.